BIOSERGEN AS
7075 TILLER
Return on Equity
−485,43 %
Current Ratio
0,89
Debt-to-Equity Ratio
0
Key figures (NOK) | 2022 | |
---|---|---|
Revenue | 1 753 000 | |
Net Income | −15 888 000 | |
Total Assets | 16 525 000 | |
Total Equity | 3 273 000 |
Income (NOK) | 2022 | |
---|---|---|
Revenue | 1 753 000 | |
Expenditure | 17 011 000 | |
Operating Profit | −15 259 000 | |
Financial Income | 439 000 | |
Financial Costs | 1 068 000 | |
Financial Balance | −629 000 | |
Earnings Before Tax | −15 888 000 | |
Tax | 0 | |
Net Income | −15 888 000 |
Balance (NOK) | 2022 | |
---|---|---|
Total Fixed Assets | 4 791 000 | |
Total Current Assets | 11 734 000 | |
Total Assets | 16 525 000 | |
Total Retained Equity | −15 888 000 | |
Total Equity | 3 273 000 | |
Total Long-Term Debt | 0 | |
Total Current Debt | 13 253 000 | |
Total Equity and Debt | 16 525 000 |
Cash flow (NOK) | 2022 | |
---|---|---|
Sales Income | 75 000 | |
Other Income | 1 678 000 | |
Revenue | 1 753 000 | |
Cost of Goods Sold | 13 102 000 | |
Salary Costs | 0 | |
Depreciation | 0 | |
Impairment | 0 | |
Expenditure | 17 011 000 | |
Operating Profit | −15 259 000 | |
Financial Income | 439 000 | |
Financial Costs | 1 068 000 | |
Financial Balance | −629 000 | |
Dividends | 0 | |
Net Income | −15 888 000 |
Balance details (NOK) | 2022 | |
---|---|---|
Goodwill | 0 | |
Total Intangible Assets | 0 | |
Real Eastate | 0 | |
Machinery and Plant Facilities | 0 | |
Fixtures | 0 | |
Total Tangible Assets | 0 | |
Total Fiancial Fixed Assets | 4 791 000 | |
Total Fixed Assets | 4 791 000 | |
Stock | 0 | |
Total Investments | 0 | |
Cash, Bank | 62 000 | |
Total Current Assets | 11 734 000 | |
Total Assets | 16 525 000 | |
Total Equity | 3 273 000 | |
Short-Term Group Debt | 7 485 000 | |
Total Long-Term Debt | 0 | |
Creditors | 3 357 000 | |
Unpaid Taxes | 0 | |
Dividends | 0 | |
Other Current Debt | 2 410 000 | |
Total Current Debt | 13 253 000 | |
Total Equity and Debt | 16 525 000 |
Financial indicators | 2022 | |
---|---|---|
Return on Equity | −485,43 % | |
Debt-to-Equity Ratio | 0 | |
Operating Profit Margin | −870,45 % | |
Current Ratio | 0,89 | |
Quick Ratio | 0,89 | |
Equity Ratio | 0,2 | |
Gross Profit Margin | −647,4 % |
Rotate your device to see the full table
More companies from 7075 TILLER
NILS DANIEL AUNES REISELEGAT
OI HÅR OG VELVÆRESENTER AS
RØRENTREPRENØRENES OPPLÆRINGSKONTOR - TRØNDELAG
OTIS MIDT-NORGE BEDRIFTSIDRETTSLAG
ROGER ASKIM
HAAKON VII'S GATE 11 AS
DANS I MIDT NORGE Geir Pedersen
DEN VIETNAMESISKE BUDDHISTISKE & KULTURELLE FORENINGEN I TRØNDELAG
MONA BRUVOLL FYSIOTERAPI
TRONDHEIM TAK AS
KASH HOLDING AS
ØSTRE ROSTEN 76 AS
KALLAND HOLDING AS
STEFF INVEST AS
OLE DRAGSTEN INVEST AS
More companies within Research and experimental development on biotechnology
LYNGSTADAAS BIOMEDICAL CONSULTING AS
SENSE BIOPHARMA AS
BIOBANK AS
BERGER FELTBIO
BEJO HOLDING AS
RØNOLD CONSULTING AS
ZYM HOLDING AS
ECO ENERGY HOLDING AS
BERGERSEN NATURGALLERI
LIFECARE ASA
NYKODE THERAPEUTICS ASA
PCI BIOTECH HOLDING ASA
CALYSTA AS
AKVAINVEST MØRE OG ROMSDAL AS
GOLDEN OMEGA NORWAY AS
See all ->